Molecular Pathogenesis of Brain Damage and Gene Therapy in Genetic Leukodystrophy

遗传性脑白质营养不良脑损伤的分子发病机制和基因治疗

基本信息

  • 批准号:
    11470176
  • 负责人:
  • 金额:
    $ 9.54万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    1999
  • 资助国家:
    日本
  • 起止时间:
    1999 至 2001
  • 项目状态:
    已结题

项目摘要

1. Pathogenesis of Leukodystrophy in Globoide Cell Leukodystrophy and Other1) Using animal model of Krabbe globoid cell leukodystrophy(GLD), we tried to identified the cause of leukodytrophy in twitcher mice. The cause of neural cell damage might be caused by the influx of intracellular calcium in such mice which was demonstrated by patch cramp method. The increased intracellular calcium resulted in the activation of cellular protease and hense damage the neural cells.2) We studied the clinical phnotype and genotype in metachromatic leukodystrophy and also identified novel genotype in two cases with MLD. Furthermore, we demonstrated that the G99D mutation was neruological severe type and consisted of 50% of all genotype of Japanese MLD.3) Japanese patients with Sjogren Larrson syndrome shows particular genotype in Japanese.4) We studied the genotype identifications in Fabry disease which were L16H, A37V, W209X, 342QIVS-1-1 etc.2. Cell therapy and gene therapy in genetic leukodystrophyGene therapy and cell therapy were carried out using Twitcher mice and Sly Mice.1) Twitcher mice were treated with adenovirus vector which was administered into intraventricle, during fetal period. The number of globoid cells were decreased in treated animals after the administration of viral vetor. Simultaneously, the amount of psychosine was decreased in treated animals.2) Neural stem cells obtained fromhuman fetal brains were injected into Sly mice brain and the accumulated compounds in Sly mice were decreased. The data suggest that neural stem cells were effective for the treatment of The CNS involvement in these neurological mutants.3) Injection of mesenchymal stem cells into Sly mice showed decreased storage Materials and effective for neurological mice.
1. 球状细胞脑白质营养不良及其他脑白质营养不良的发病机制1)利用Krabbe球状细胞脑白质营养不良(GLD)动物模型,我们尝试鉴定twitcher小鼠脑白质营养不良的病因。膜片痉挛法证实该小鼠神经细胞损伤的原因可能是细胞内钙离子内流所致。细胞内钙的增加导致细胞蛋白酶的激活,从而损伤神经细胞。2)我们研究了异染性脑白质营养不良的临床表型和基因型,并在两例MLD病例中发现了新的基因型。此外,我们还证明G99D突变为神经系统严重型,占日本MLD所有基因型的50%。3)日本干燥综合征患者在日语中表现出特定的基因型。4)我们研究了法布里病的基因型鉴定,包括L16H、A37V、W209X、342QIVS-1-1等2。遗传性脑白质营养不良的细胞治疗和基因治疗采用Twitcher小鼠和Sly小鼠进行基因治疗和细胞治疗。1)用腺病毒载体治疗Twitcher小鼠,在胎儿期将腺病毒载体注射入脑室内。施用病毒载体后,治疗动物的球状细胞数量减少。同时,经治疗的动物中精神嘧啶的量也减少了。2)将从人胎儿大脑中获得的神经干细胞注射到Sly小鼠大脑中,Sly小鼠体内累积的化合物减少。数据表明,神经干细胞对于治疗这些神经突变体的中枢神经系统受累是有效的。3)将间充质干细胞注射到Sly小鼠体内显示储存材料减少,并且对神经小鼠有效。

项目成果

期刊论文数量(80)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Watabe K., Ohashi T., Sakamoto T., Kawazoe Y., Takeshima T., Oyanagi K., Inoue K., Eto Y., and Kim S.U.: "Rescue of lesioned adult rat spinal motoneurons by adenoviral gene transfer of glial cell line-derived neurotrophic factor."Journal of Neuroscience R
Watabe K.、Ohashi T.、Sakamoto T.、Kawazoe Y.、Takeshima T.、Oyanagi K.、Inoue K.、Eto Y. 和 Kim S.U.:“通过胶质细胞腺病毒基因转移来拯救受损的成年大鼠脊髓运动神经元
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Oishi K., , Ida H., Eto Y., et al.: "Clinical and molecular of Japanese patients with neuronal・・・"Molecular Genetics and Metabolism. 66. 344-348 (1999)
Oishi K., , Ida H., Eto Y., et al.:“日本神经元患者的临床和分子......”分子遗传学和代谢 66. 344-348 (1999)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kimura T, Ohashi T, Eto Y, et al.: "The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial・・・"Cancer. 92. 2555-2561 (2001)
Kimura T、Ohashi T、Eto Y 等人:“FGFR3 基因致死性发育不良突变的发生率在低级别或浅表性癌症中较高……”癌症。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Watabe K, Ida H, Eto Y, et al: "Establishment and characterization of immortalized Schwann cells from murine model of Nieman-Pick disease C(spm/spm)"J Peripheral Nervous System. 6. 85-94 (2001)
Watabe K、Ida H、Eto Y 等人:“来自尼曼匹克病 C(spm/spm) 小鼠模型的永生化雪旺细胞的建立和表征”J 周围神经系统。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Eto Y, Ohashi T: "Gene therapy/ cell therapy for lysosomal strange disease."J Inhert Metab Dis. 23(3). 293-298 (2000)
Eto Y、Ohashi T:“溶酶体奇怪疾病的基因疗法/细胞疗法。”J Inhert Metab Dis。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ETO Yoshikatsu其他文献

ETO Yoshikatsu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ETO Yoshikatsu', 18)}}的其他基金

Anti-CD3 antibody induced immune tolerance to infused enzyme in enzyme replacement therapy for lysosomal storage disease
抗 CD3 抗体在溶酶体贮积病酶替代疗法中诱导对输注酶的免疫耐受
  • 批准号:
    21591333
  • 财政年份:
    2009
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Immune tolerance induction in enzyme replacement therapy for lysosomal storage diseases
溶酶体贮积病酶替代疗法中的免疫耐受诱导
  • 批准号:
    19591223
  • 财政年份:
    2007
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of novel therapy and elucidation of pathophysiology for genetic leukodystrophy
遗传性脑白质营养不良新疗法的开发和病理生理学的阐明
  • 批准号:
    14370252
  • 财政年份:
    2002
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Prenatal Diagnosis of Ingenited Metabolic Disorders Using Maternal Blood
利用母血对先天性代谢紊乱进行产前诊断
  • 批准号:
    11557061
  • 财政年份:
    1999
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Studies for Gene Therapy of Sphingolipidosis
鞘脂沉积症基因治疗研究
  • 批准号:
    10044321
  • 财政年份:
    1998
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
The cause of neuropathochemistry of inherited Neurodegeneration
遗传性神经变性的神经病理化学原因
  • 批准号:
    08457232
  • 财政年份:
    1996
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Modified enzyme which target to neuronal cells to cross blood brain barrier
修饰酶靶向神经元细胞穿过血脑屏障
  • 批准号:
    02557042
  • 财政年份:
    1989
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Developmental Scientific Research (B)
Pathogenesis of Multiple Sulfatase Deficiency
多种硫酸酯酶缺乏症的发病机制
  • 批准号:
    01570550
  • 财政年份:
    1989
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
Molecular and biochemical analysis of inherited degernerative brain disorder
遗传性退行性脑部疾病的分子和生化分析
  • 批准号:
    61480223
  • 财政年份:
    1986
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)

相似海外基金

ICF: A novel dual-target gene therapy for safe and efficacious treatment of chronic non-infectious uveitis
ICF:一种安全有效治疗慢性非感染性葡萄膜炎的新型双靶点基因疗法
  • 批准号:
    MR/Z50385X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Research Grant
Next-generation automation and PAT implementation for QbD and enhanced approaches for cell and gene therapy
QbD 的下一代自动化和 PAT 实施以及细胞和基因治疗的增强方法
  • 批准号:
    10087446
  • 财政年份:
    2024
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Collaborative R&D
Longitudinal structural and cognitive functional imaging and outcome prediction in focal epilepsy treated with gene therapy and surgical resection.
基因治疗和手术切除治疗局灶性癫痫的纵向结构和认知功能成像及结果预测。
  • 批准号:
    MR/X031039/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Research Grant
Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
  • 批准号:
    MR/Y019458/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Research Grant
GeneT: The Gene Therapy CoE at the Center of Portugal
GeneT:葡萄牙中心的基因治疗 CoE
  • 批准号:
    10090933
  • 财政年份:
    2024
  • 资助金额:
    $ 9.54万
  • 项目类别:
    EU-Funded
SBIR Phase I: Development of an Adjustable Gene Therapy Platform Technology
SBIR 第一阶段:可调节基因治疗平台技术的开发
  • 批准号:
    2240683
  • 财政年份:
    2023
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Standard Grant
Exploration novel effects of SHED-TK-derived exosomes on TK/GCV suicide gene therapy
探索SHED-TK衍生的外泌体对TK/GCV自杀基因治疗的新作用
  • 批准号:
    23K15643
  • 财政年份:
    2023
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Gene expression profiling of skin ulcers for short-acting in vivo gene therapy
皮肤溃疡的基因表达谱用于短效体内基因治疗
  • 批准号:
    23K19673
  • 财政年份:
    2023
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Activation of long non-coding RNA by a gene therapy CRISPR/Cas9 approach to prevent vein graft failure
通过基因治疗 CRISPR/Cas9 方法激活长非编码 RNA 以预防静脉移植失败
  • 批准号:
    EP/X024563/1
  • 财政年份:
    2023
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Research Grant
Developing a gene therapy product to treat pressure ulcers in lower-limb amputees
开发一种基因治疗产品来治疗下肢截肢者的压力性溃疡
  • 批准号:
    2888189
  • 财政年份:
    2023
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了